The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: A clinicopathologic and immunohistochemical study of 12 cases at a single institution

I. Wei Chang, Jui Wei Lin, You Ting Wu

研究成果: 雜誌貢獻文章

5 引文 (Scopus)

摘要

Meningeal hemangiopericytoma (HPC) is a clinicopathologically well-characterized malignancy with a high tendency to recur locally and to metastasize outside the central nervous system (CNS). We render clinicopathologic features of 12 cases of this uncommon tumor to further elucidate the relationship between the status of the DNA-repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT) and the prognosis. Twenty-five specimens of meningeal HPC belonging to 12 patients were obtained at a single institution from 1992 to 2001. Correlations of histologic parameters, immunohistochemical study and clinical features were assessed. This series included five men and seven women with a median age of 37.5 years at the first surgery. The median post-operative follow-up period was 7.6 years. Six patients (55%) had single or multiple local tumor recurrences. The mean time to recurrence was 6.7 years. Distant metastasis occurred in three patients (27%) at a mean time of 6.5 years after first operation. The most frequent metastatic sites were liver and lung. Histopathologically, eight primary tumors (67%) belonged to WHO grade II, while four primary tumors (33%) belonged to WHO grade III. Immunohistochemically, 18% primary tumors exhibited 3+ to 4+ nuclear staining for MGMT protein, 18% exhibited 2+ staining, and 64% exhibited 0 to 1+ staining. The overall survival rate was 67 and 33% for primary tumors with 0 to 1+ and 2+ to 4+ MGMT staining, respectively (P = 0.018). The study illustrates aggressive behavior of meningeal HPC and the prognostic value of the status of MGMT protein expression.
原文英語
頁(從 - 到)563-572
頁數10
期刊Journal of Neuro-Oncology
105
發行號3
DOIs
出版狀態已發佈 - 十二月 1 2011
對外發佈Yes

指紋

Protein Methyltransferases
Hemangiopericytoma
DNA
Neoplasms
Staining and Labeling
O(6)-Methylguanine-DNA Methyltransferase
DNA Repair Enzymes
Recurrence
Methyltransferases
O-(6)-methylguanine
Survival Rate
Central Nervous System
Neoplasm Metastasis
Lung
Liver

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

引用此文

@article{b7832fe7accf453d9727c160b57b9db6,
title = "The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma: A clinicopathologic and immunohistochemical study of 12 cases at a single institution",
abstract = "Meningeal hemangiopericytoma (HPC) is a clinicopathologically well-characterized malignancy with a high tendency to recur locally and to metastasize outside the central nervous system (CNS). We render clinicopathologic features of 12 cases of this uncommon tumor to further elucidate the relationship between the status of the DNA-repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT) and the prognosis. Twenty-five specimens of meningeal HPC belonging to 12 patients were obtained at a single institution from 1992 to 2001. Correlations of histologic parameters, immunohistochemical study and clinical features were assessed. This series included five men and seven women with a median age of 37.5 years at the first surgery. The median post-operative follow-up period was 7.6 years. Six patients (55{\%}) had single or multiple local tumor recurrences. The mean time to recurrence was 6.7 years. Distant metastasis occurred in three patients (27{\%}) at a mean time of 6.5 years after first operation. The most frequent metastatic sites were liver and lung. Histopathologically, eight primary tumors (67{\%}) belonged to WHO grade II, while four primary tumors (33{\%}) belonged to WHO grade III. Immunohistochemically, 18{\%} primary tumors exhibited 3+ to 4+ nuclear staining for MGMT protein, 18{\%} exhibited 2+ staining, and 64{\%} exhibited 0 to 1+ staining. The overall survival rate was 67 and 33{\%} for primary tumors with 0 to 1+ and 2+ to 4+ MGMT staining, respectively (P = 0.018). The study illustrates aggressive behavior of meningeal HPC and the prognostic value of the status of MGMT protein expression.",
keywords = "Hemangiopericytoma, Immunohistochemistry, Meningeal, MGMT",
author = "Chang, {I. Wei} and Lin, {Jui Wei} and Wu, {You Ting}",
year = "2011",
month = "12",
day = "1",
doi = "10.1007/s11060-011-0620-7",
language = "English",
volume = "105",
pages = "563--572",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - The status of MGMT protein expression is a prognostic factor for meningeal hemangiopericytoma

T2 - A clinicopathologic and immunohistochemical study of 12 cases at a single institution

AU - Chang, I. Wei

AU - Lin, Jui Wei

AU - Wu, You Ting

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Meningeal hemangiopericytoma (HPC) is a clinicopathologically well-characterized malignancy with a high tendency to recur locally and to metastasize outside the central nervous system (CNS). We render clinicopathologic features of 12 cases of this uncommon tumor to further elucidate the relationship between the status of the DNA-repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT) and the prognosis. Twenty-five specimens of meningeal HPC belonging to 12 patients were obtained at a single institution from 1992 to 2001. Correlations of histologic parameters, immunohistochemical study and clinical features were assessed. This series included five men and seven women with a median age of 37.5 years at the first surgery. The median post-operative follow-up period was 7.6 years. Six patients (55%) had single or multiple local tumor recurrences. The mean time to recurrence was 6.7 years. Distant metastasis occurred in three patients (27%) at a mean time of 6.5 years after first operation. The most frequent metastatic sites were liver and lung. Histopathologically, eight primary tumors (67%) belonged to WHO grade II, while four primary tumors (33%) belonged to WHO grade III. Immunohistochemically, 18% primary tumors exhibited 3+ to 4+ nuclear staining for MGMT protein, 18% exhibited 2+ staining, and 64% exhibited 0 to 1+ staining. The overall survival rate was 67 and 33% for primary tumors with 0 to 1+ and 2+ to 4+ MGMT staining, respectively (P = 0.018). The study illustrates aggressive behavior of meningeal HPC and the prognostic value of the status of MGMT protein expression.

AB - Meningeal hemangiopericytoma (HPC) is a clinicopathologically well-characterized malignancy with a high tendency to recur locally and to metastasize outside the central nervous system (CNS). We render clinicopathologic features of 12 cases of this uncommon tumor to further elucidate the relationship between the status of the DNA-repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT) and the prognosis. Twenty-five specimens of meningeal HPC belonging to 12 patients were obtained at a single institution from 1992 to 2001. Correlations of histologic parameters, immunohistochemical study and clinical features were assessed. This series included five men and seven women with a median age of 37.5 years at the first surgery. The median post-operative follow-up period was 7.6 years. Six patients (55%) had single or multiple local tumor recurrences. The mean time to recurrence was 6.7 years. Distant metastasis occurred in three patients (27%) at a mean time of 6.5 years after first operation. The most frequent metastatic sites were liver and lung. Histopathologically, eight primary tumors (67%) belonged to WHO grade II, while four primary tumors (33%) belonged to WHO grade III. Immunohistochemically, 18% primary tumors exhibited 3+ to 4+ nuclear staining for MGMT protein, 18% exhibited 2+ staining, and 64% exhibited 0 to 1+ staining. The overall survival rate was 67 and 33% for primary tumors with 0 to 1+ and 2+ to 4+ MGMT staining, respectively (P = 0.018). The study illustrates aggressive behavior of meningeal HPC and the prognostic value of the status of MGMT protein expression.

KW - Hemangiopericytoma

KW - Immunohistochemistry

KW - Meningeal

KW - MGMT

UR - http://www.scopus.com/inward/record.url?scp=82955213035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955213035&partnerID=8YFLogxK

U2 - 10.1007/s11060-011-0620-7

DO - 10.1007/s11060-011-0620-7

M3 - Article

C2 - 21667225

AN - SCOPUS:82955213035

VL - 105

SP - 563

EP - 572

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -